Phase II Study of Vx001 Vaccine in HLA-A*0201 Positive Patients With TERT Positive Stage IV or Recurrent Stage I-III NSCLC

Trial Profile

Phase II Study of Vx001 Vaccine in HLA-A*0201 Positive Patients With TERT Positive Stage IV or Recurrent Stage I-III NSCLC

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Dec 2017

At a glance

  • Drugs Vx 001 (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms VaxLung
  • Sponsors Vaxon Biotech
  • Most Recent Events

    • 23 Jun 2017 This trial has been discontinued in Greece (end date: 5 Mar 2017).
    • 01 Jun 2017 According to a Vaxon biotech media release, results will be presented at at the ESMO.
    • 01 Jun 2017 Status changed from active, no longer recruiting to completed, according to a Vaxon Biotech Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top